Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

The Trump administration is said to be considering closing the CDC's Division of HIV Prevention (DHP), a plan that leaves ...

Nearly 85% of the 1.7 million adolescents with HIV live in sub-Saharan Africa, along with half of the nearly 40 million ...

The ALLIANCE trial is the first randomized clinical trial of TAF- vs TDF-based regimens in treatment naïve adults with HIV/HBV coinfection. Its goal is to evaluate treatment regimens that may ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

The global HIV antivirals market is experiencing substantial growth, fueled by rising global awareness, advancements in pharmaceutical research, and the increasing adoption of innovative treatment ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

Weight trajectories differed significantly among patients with HIV during the first year of ART, with no associations observed between weight gain and type of ART regimen.

TAIPEI, March 18, 2025 /PRNewswire/ -- TaiMed Biologics (4147 TWO), an innovation-driven biotech company, has Phase 2a ...

A dissolvable oral dispersible film of dolutegravir could transform treatment ANALYSIS | MELODY CHIRONDA | In the fight ...